Targeting breast cancer metastasis with inhibitors of Id-1

使用 Id-1 抑制剂靶向乳腺癌转移

基本信息

批准号：
8516812
负责人：
Anuradha Mahadevan
金额：
$ 28.98万
依托单位：
ORGANIX, INC.
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-05-01 至 2015-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8516812
关键词：
Adverse effects BHLH Protein Breast Breast Cancer Cell Cannabidiol Cell Differentiation process Cell Line Cell Proliferation Cells Cessation of life Chronic Complement Data Development Disseminated Malignant Neoplasm Down-Regulation Drug Design Drug Kinetics Family Future Gene Expression Goals Growth Helix-Turn-Helix Motifs Housing Human Inhibition of Cell Proliferation Lead Legal patent Libraries Malignant Neoplasms Measures Neoplasm Metastasis Normal Cell Outcome Paclitaxel Patients Pharmaceutical Preparations Phase Plants Plasma Proteins Pre-Clinical Model Prevention Property Protein Binding Proteins Route Small Business Innovation Research Grant Specificity Staging Stream Therapeutic Therapeutic Intervention Tissues Toxic effect Tumor Cell Invasion Work analog base cancer cell carcinogenesis clinical practice cytotoxic cytotoxicity design in vivo inhibitor/antagonist malignant breast neoplasm neoplastic cell novel novel therapeutic intervention phase 2 study public health relevance screening treatment strategy tumor growth

项目摘要

DESCRIPTION (provided by applicant): Metastasis of aggressive breast cancer is a devastating and ultimately fatal condition. The current first- line agents which are used to treat breast cancer metastasis primarily target tumor growth. These drugs produce only modest increases in survival in patients with aggressive metastatic cancers and have significant side effects. Currently, there are no available treatment options that can specifically and effectively inhibit tumor invasion and metastasis. Therefore, novel drug strategies are needed to treat this chronic, fatal and incurable condition. Our therapeutic strategy for the treatment of aggressive breast cancer is based on reducing Id-1 expression. Id-1 is a key regulator of the invasive and metastatic potential of breast and additional cancers. In this Phase I proposal our focus will be on the optimization of our lead compound to discover one or more analogs that down-regulate Id-1 expression and consequently inhibit breast cancer cell invasion and metastasis. We will also optimize these compounds so that they display a favorable ADME-Tox profile. The ultimate goal of this proposal is to develop a novel therapeutic approach for the treatment of metastatic human breast cancers by down-regulation of Id-1.

描述（由申请人提供）：侵袭性乳腺癌的转移是一种毁灭性的、最终致命的疾病。目前用于治疗乳腺癌转移的一线药物主要针对肿瘤生长。这些药物只能适度提高侵袭性转移性癌症患者的生存率，并且具有显着的副作用。目前，尚无能够特异性、有效抑制肿瘤侵袭和转移的治疗方案。因此，需要新的药物策略来治疗这种慢性、致命且无法治愈的疾病。我们治疗侵袭性乳腺癌的治疗策略是基于减少 Id-1 表达。 Id-1 是乳腺癌和其他癌症侵袭和转移潜力的关键调节因子。在此一期提案中，我们的重点将是优化我们的先导化合物，以发现一种或多种下调 Id-1 表达并从而抑制乳腺癌细胞侵袭和转移的类似物。我们还将优化这些化合物，使它们表现出良好的 ADME-Tox 特征。该提案的最终目标是开发一种新的治疗方法，通过下调 Id-1 来治疗转移性人类乳腺癌。